Advanced Filters
noise

atrial-fibrillation Clinical Trials

A listing of atrial-fibrillation medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Found 500 clinical trials
J Johan Engdahl, MD, PhD

Atrial Fibrillation Screening Post Ischemic Cerebrovascular Events

Stroke is one of the leading causes behind death and permanent disability in adults. Atrial fibrillation (AF) is the most common clinical arrhythmia and its prevalence is steeply increasing with age. Atrial fibrillation is associated with a manifold increase in the risk for stroke. It is considered important to investigate …

70 - 100 years of age Both Phase N/A
J Jeroen Ludikhuize, MD, PhD, MSc

Peri-Operative Magnesium Infusion to Prevent Atrial Fibrillation Evaluated.

Post-operative atrial fibrillation (POAF) is commonly observed in patients post cardiac surgery without a previous history of atrial fibrillation (AF) or other arrythmias. It's associated with significant postoperative complications including infection, bleeding reoperation, increased hospital length of stay (LOHS) and mortality. Magnesium has been identified as a potentially interesting compound …

18 - 100 years of age Both Phase 2/3
M Mahmoud Abdelhay

Impact of Education Level on Clinical Outcomes in Self-INR Managed Patients

Oral anticoagulation (OAC) is indicated in a wide variety of clinical conditions including atrial fibrillation (AF), mechanical valve prosthesis (MVP), deep vein thrombosis and pulmonary embolism. Although direct OAC has replaced vitamin K antagonists (VKA) in non-valvular AF due to lower bleeding risk, it's still recommended to use VKA specifically …

18 - 100 years of age Both Phase N/A
B BumJoon Kim

Cardea SOLOTM for Paroxysmal Atrial Fibrillation Diagnosis in ESUS Patients With Left Atrial Enlargement

The aim of the study is to evaluate the efficacy and safety of the Cardea SOLO Compared to 12 lead EKG for Paroxysmal Atrial Fibrillation Diagnosis in ESUS patients with Left Atrial Enlargement.

19 - 100 years of age Both Phase N/A
J Jingfeng Wang, M.D.

Using Cryoballoon Ablation as Initial Treatment for Persistent Atrial Fibrillation

This study is to assess the effectiveness and safety of using cryoballoon ablation comparing with anti-arrhythmic drug therapy as initial treatment for naive patients with persistent atrial fibrillation.

18 - 75 years of age Both Phase N/A
J José Luis Merino, MD

SUbstrate Ablation in Persistent Atrial Fibrillation for Elimination of Recurrences (SUPAFER).

Antecedents: electrical isolation of pulmonary veins is the standard treatment for patients with atrial fibrillation. However, its efficacy is lower in persistent and chronic forms of this arrhythmia compared to paroxysmal atrial fibrillation. Many complementary techniques have been proposed, that added to pulmonary veins isolation, may reduce the recurrence rate …

18 - 100 years of age Both Phase N/A
S Shohreh Honarbakhsh, MRCP, BSc, PhD

Personalised Ablation Strategies in AF

Atrial fibrillation (AF) is the most common arrhythmia with an expected rise in prevalence over the next decade. Catheter ablation is a safe treatment option in eliminating AF however, success rates still remains variable. Existing strategies do not take into account the differences in AF perpetuation mechanisms beyond the pulmonary …

18 - 100 years of age Both Phase N/A
B Bogdan Okiljević

Silymarin for the Prevention of Atrial Fibrillation After Cardiac Surgery

The study is a prospective, randomized, controlled trial to assess the effects of silymarin on the occurrence of postoperative atrial fibrillation after coronary artery bypass graft surgery.

18 - 85 years of age Both Phase 3
P Prachi Mehndiratta

Screening for Atrial Fibrillation in Elderly Women Older Than 70 Years

Screening for Atrial Fibrillation in Elderly Women (SAFE-W) is a pilot study evaluating the prevalence of atrial fibrillation (Afib) in a rapidly aging segment of the population. Studies have shown that women with Afib are more likely to be symptomatic, have increased mortality from stroke resulting from Afib, and are …

70 - 100 years of age Female Phase N/A
D David McAlpine, MD

MAGNAM Trial, Magnesium Versus Amiodarone in Atrial Fibrillation in Critical Care

A multi-centre, non-blinded, comparative effectiveness, randomised controlled trial. Patients will be prospectively enrolled from Critical Care Units and will be assessed for study enrollment based on inclusion/exclusion criteria at the time of the onset of fast atrial fibrillation (AF)(irregular and often rapid heart rate). The authors hypothesize that high dose …

18 - 100 years of age Both Phase 3

Rewrite in simple language using AI